39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 39,241 shares of the company’s stock, valued at approximately $705,000.

Other institutional investors also recently bought and sold shares of the company. Seven Fleet Capital Management LP boosted its holdings in Amylyx Pharmaceuticals by 44.1% in the 1st quarter. Seven Fleet Capital Management LP now owns 16,671 shares of the company’s stock worth $232,000 after buying an additional 5,100 shares during the last quarter. Stempoint Capital LP raised its holdings in shares of Amylyx Pharmaceuticals by 18.5% during the first quarter. Stempoint Capital LP now owns 669,685 shares of the company’s stock valued at $9,309,000 after acquiring an additional 104,545 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Amylyx Pharmaceuticals by 11.6% during the first quarter. Janus Henderson Group PLC now owns 4,986,073 shares of the company’s stock valued at $69,257,000 after acquiring an additional 520,201 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Amylyx Pharmaceuticals by 12.4% in the first quarter. ADAR1 Capital Management LLC now owns 1,000,604 shares of the company’s stock valued at $13,908,000 after acquiring an additional 110,248 shares in the last quarter. Finally, Amundi purchased a new position in shares of Amylyx Pharmaceuticals in the first quarter valued at approximately $179,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

AMLX opened at $38.60 on Thursday. The company’s 50 day simple moving average is $19.38 and its two-hundred day simple moving average is $16.35. Amylyx Pharmaceuticals, Inc. has a 1-year low of $7.82 and a 1-year high of $39.07. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of -26.99 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Key Amylyx Pharmaceuticals News

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Phase 3 success strengthens the product outlook. Avexitide met both the primary and secondary endpoints in the LUCIDITY trial, reducing hypoglycemic events by 55% in patients with PBH. The results provide Amylyx with a potentially important late-stage asset and support plans to submit an FDA application by the end of 2026. Reuters report on the avexitide trial
• Positive Sentiment: Analysts raised targets and ratings. Guggenheim lifted its target to $55 and assigned a “buy” rating; Robert W. Baird raised its target to $52 with an “outperform” rating; and H.C. Wainwright increased its target to $55 while maintaining a “buy” rating. Wolfe Research also upgraded the shares to “strong buy.” Benzinga analyst-rating updates
• Positive Sentiment: Investors are pricing in commercialization potential. Coverage characterized the trial as a major catalyst that could move avexitide closer to regulatory review and eventual commercialization, helping explain the unusually high trading activity and fresh stock high. Zacks analysis of Amylyx’s Phase 3 win
• Neutral Sentiment: Important milestones remain ahead. The results are topline data, so additional analysis, regulatory discussions, a formal FDA filing, and approval are still required. Commentary also cautioned that the sharp rally may have moved ahead of near-term fundamentals, increasing volatility and profit-taking risk. Invezz analysis of AMLX risks

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMLX. Robert W. Baird lifted their price target on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday. Guggenheim increased their price objective on Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright lifted their target price on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Amylyx Pharmaceuticals has an average rating of “Buy” and a consensus target price of $36.25.

Amylyx Pharmaceuticals Company Profile

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs.